Human β-defensin-1

Human β-defensin-1 (MOI of 1; 24 h) significantly restricts IAV replication in human HBEpCs, reducing matrix gene copy numbers by 99%^[2].

Human β-defensin-1 overexpression (MOI 0.5-1.0; 24 h) upregulated STAT3 protein expression and its phosphorylation at Tyr705 in HBEpCs, both in uninfected and A (H1N1)-infected cells^[2].

Human β-defensin-1 (HβD-1) (10-20 µg/mL; 3-24 h) enhances angiogenin secretion from normal human dermal fibroblasts in a dose-and time-dependent manner^[1].
Human β-defensin-1 (20 μg/mL; 30-180 min) induces phosphorylation of EGFR in normal human dermal fibroblasts^[1].
Human β-defensin-1 (20 μg/mL; 6 h) enhances angiopoietin production in normal human dermal fibroblasts through the EGFR pathway^[1].
Human β-defensin-1 (20 μg/mL; 30-120 min) induces Src phosphorylation in normal human dermal fibroblasts^[1].
Human β-defensin-1 (20 µg/mL) mediates angiogenin secretion in normal human dermal fibroblasts via the Src signaling pathway^[1].
Human β-defensin-1 (20 µg/mL) mediates angiogenin secretion by normal human dermal fibroblasts through the NF-κB signaling pathway^[1].
Human β-defensin-1 (20 µg/mL; 5-60 min) induces phosphorylation of p38, JNK, and ERK1/2 in normal human dermal fibroblasts^[1].
Human β-defensin-1 (20 µg/mL; 6 h)-mediated angiogenin production in normal human dermal fibroblasts requires activation of the p38 and JNK pathways, but not the ERK pathway^[1].
Human β-defensin-1 (20 µg/mL; 60 min) induces nuclear translocation of NF-κB in normal human dermal fibroblasts^[1].
Human β-defensin-1 (500 ng/mL; 1-3 h) co-incubated with DGC-treated human sperm significantly maintained sperm motility for up to 2 hr and sperm viability for up to 3 hr^[3].